Nivolumab in the treatment of metastatic squamous non-small cell lung . . . Abstract Progress in the treatment of patients with advanced stage squamous cell non-small cell lung cancer (NSCLC) has been limited An improvement in the understanding of tumor immunosurveillance has resulted in the development of the immune checkpoint inhibitors such as nivolumab
Non-Small Cell Lung Cancer (NSCLC) Treatment | OPDIVO® (nivolumab) OPDIVO® (nivolumab) alone, or with YERVOY® (ipilimumab) can be used as an immunotherapy treatment option for adults with certain types of NSCLC Please see Indication and Important Safety Information
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 . . . Immunotherapy-based regimens are now standard first-line treatments for patients with metastatic non-small cell lung cancer (mNSCLC) Nivolumab and ipilimumab are immune checkpoint inhibitors that block programmed death 1 (PD-1) and cytotoxic T lymphocyte associated protein-4 (CTLA-4), respectively, through distinct but complementary mechanisms of action [1,2] First-line nivolumab plus
Nivolumab plus ipilimumab versus carboplatin-based doublet as first . . . Background: Combined treatment with anti-PD-1 and anti-CTLA-4 antibodies has shown superiority over chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC), but data for older patients (aged ≥70 years) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 or those with an ECOG performance status of 2
Nivolumab and Chemotherapy for Early-Stage Lung Cancer In the CheckMate 816 trial, people with early-stage non-small cell lung cancer (stage IB to IIIA) received either nivolumab (Opdivo) and chemotherapy or chemotherapy alone before surgery